Since the beginning of this year, the domestic medicine and medical and health fields have been very hot
.
According to the data, from January to August, there were a total of 1,026 financing events in the national biomedical industry, with a cumulative amount of 89.
174 billion yuan
.
Since September, a large number of pharmaceutical companies have announced the completion of financing, including Saipu Biologics, Youjia Biologics, Kemi Biologics, etc
.
On September 23, Youjia (Hangzhou) Biomedical Technology Co.
, Ltd.
(hereinafter referred to as Youjia Biologics) announced the completion of tens of millions of yuan A+ round of financing, which is exclusively led by Shaanxi Investment Growth
.
This round of funding is mainly used to promote the IND declaration of Youjia liver fibrosis project YJH-0425 and other preclinical research of multiple product pipelines
.
It is understood that Youjia Bio has built an intelligent NDDS system for target selection and sequence design, a third-generation CMS3 modification technology for chemical modification, and a diversified delivery system for CPNP, PNAC and LNP that has independent intellectual property rights and meets a variety of drug delivery methods and targeting, which greatly shortens the research and development cycle and research and development costs, and its self-developed FIC product 0425 is expected to submit IND applications
at the end of 2022.
On the same day, there was news that Chimigen Bio Co.
, Ltd.
(Chengdu) also announced the completion of the first round of financing
of more than 100 million yuan in recent days.
This round of funds raised will accelerate the entry of the two debut products into clinical trials, expand the international team and attract professional talents
.
Kemi Bio is an innovative biotechnology company focusing on the development of advanced immunotherapy against viruses and tumors, with an international team and a global vision, committed to the breakthrough
of innovative therapies for refractory diseases.
On September 19, Saipu Bio also announced that the company completed a series B financing
of hundreds of millions of yuan.
This round of financing is jointly invested by Yuansheng Venture Capital and CICC Venucia Fund, followed by Xiamen Venture Capital and Zhongxin Group, and the old shareholders Sunshine Ronghui, Oriental Jiafu, Jiale Capital, Yuanhe High Hope, Yuanhe Holdings and Shun Financing Capital continue to be blessed
.
The funds raised will be used to further consolidate the research and development and production of high-end biomedical consumables, accelerate the development and promotion of biopharmaceutical consumables, increase the development of the international market, and move towards
a higher level, a wider range and a deeper field.
.
.
.
.
.
.
As a whole, it can be seen that financing in the biomedical field is very hot, and these financing companies also pay great attention to the construction of technology platforms and the research and development of new products, most of which raise funds to promote product research and development and clinical
.
In this regard, the industry believes that this means that investors from all walks of life are also particularly optimistic about the market prospects
of this field and related products.
It is understood that in fact, since the beginning of this year, the biomedical industry has been constantly setting off a wave of
financing.
The data shows that in the first quarter, the financing of China's biomedical field (excluding in vitro diagnosis and testing, etc.
) was very active as a whole, and more than 90 Chinese biomedical companies completed different rounds and nature of financing
.
According to the current trend, the industry expects that in the fourth quarter of the pharmaceutical field financing case, biomedical companies will still be favored objects
.
